Utility of [18F]FDG- PET/CT in Initial Staging and Management of Patients with Esophageal Carcinoma: A Tertiary Care Center Experience

[18F]FDG-PET/CT在食管癌患者初始分期和治疗中的应用:一家三级医疗中心的经验

阅读:1

Abstract

AIM OF THE STUDY: This study aims to study the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) findings in the initial staging and management of patients with esophageal carcinoma. MATERIALS AND METHODS: In this prospective study, we evaluated 74 patients with a mean age of 59.4 ± 11.6 with a range of 35-86 years. Comparison between the mean and standard deviation of SUV(max) of primary tumor between two histopathological groups, squamous cell carcinoma (SCC) and adenocarcinoma (AC) was done using unpaired Student's t-test. The mean of SUV(max) of primary tumor in relation to localized tumor to nodal to distant metastases was assessed by ANOVA test. P <0.05 was considered statistically significant. The extent of agreement between findings of contrast-enhanced computed tomography (CECT) chest and abdomen and (18)F-FDG PET/CT was done using Cohen's kappa coefficient (κ). RESULTS: Among total n = 74 (42 males and 32 females with mean age 59.4 ± 11.4; range 35-86 years) patients, SCC was seen in 78.4% and AC in 21.6% of patients. There is a progressively increased SUV(max) value of primary tumor with nodal and distant metastases. (18)F-FDG PET/CT showed disease of Stage I-II in 12.1%, Stage III in 20.2%, Stage IVA in 25.6%, and Stage IVB in 41.8% patients. There is agreement between (18)F-FDG PET/CT and CECT chest and abdomen in the evaluation of regional lymph nodes (37.8% vs. 36.4%; κ - 0.96), nonregional lymph nodes (24.3% vs. 20.2%; κ -0.74), and distant organ involvement (21.6% vs. 17.5%; κ -0.82). In addition, (18)F-FDG PET/CT found synchronous malignancies in 4.0% of patients. CONCLUSION: (18)F-FDG PET/CT metabolic parameters help in identifying metastatic involvement in morphologically equivocal and clinically suspicious lesions in carcinoma esophagus patients. Being a whole-body imaging modality, (18)F-FDG PET/CT has inbuilt advantage to detect occult, distant metastases, and synchronous malignancies for effective staging and improving plan of clinical management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。